Cytosorbents (CTSO) Operating Income Growth (1y) (2012 - 2026)
Cytosorbents (CTSO) Operating Income Growth (1y) (2012 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 199.46 Bn | 193.86 Bn | 7.27 Bn | -17.50% |
| 2 | Stryker | 127.41 Bn | 123.93 Bn | 4.50 Bn | 49.06% |
| 3 | Medtronic | 118.87 Bn | 109.65 Bn | 6.41 Bn | 30.43% |
| 4 | Boston Scientific | 73.47 Bn | 72.93 Bn | 3.85 Bn | 43.83% |
| 5 | Edwards Lifesciences | 51.95 Bn | 47.69 Bn | 1.35 Bn | 24.81% |
| 6 | Dexcom | 34.30 Bn | 32.35 Bn | 830.00 Mn | 49.72% |
| 7 | GE HealthCare Technologies | 33.76 Bn | 31.65 Bn | 2.18 Bn | 13.00% |
| 8 | Koninklijke Philips | 26.35 Bn | 23.02 Bn | 4.55 Bn | 57.74% |
| 9 | Steris | 23.04 Bn | 22.55 Bn | 684.20 Mn | 16.18% |
| 10 | Cytosorbents | 21.98 Mn | 17.56 Mn | 7.05 Mn | 27.03% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 27.03% |
| Mar 31, 2026 | 21.71% |
| Dec 31, 2025 | -29.16% |
| Sep 30, 2025 | 40.75% |
| Jun 30, 2025 | -1.26% |
| Mar 31, 2025 | 16.50% |
| Dec 31, 2024 | 63.91% |
| Sep 30, 2024 | 34.29% |
| Jun 30, 2024 | 45.57% |
| Mar 31, 2024 | 41.00% |
| Dec 31, 2023 | -48.01% |
| Sep 30, 2023 | 18.49% |
| Jun 30, 2023 | 21.51% |
| Mar 31, 2023 | -1.29% |
| Dec 31, 2022 | 33.52% |
| Sep 30, 2022 | -66.80% |
| Jun 30, 2022 | -69.70% |
| Mar 31, 2022 | -173.16% |
| Dec 31, 2021 | -262.98% |
| Sep 30, 2021 | -175.87% |